BIB ProShares Ultra NASDAQ Biotechnology

ETF 53.28 Delayed

ETF quote, holdings, sector allocation, technicals, and options analytics. Expected move IV rank history Fibonacci levels

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

BIB $53.28 —
Key stats
$53.28
52-Week Range
$36.89 – $63.20
YTD
+33.81%
IV Rank (30D)
99.02
Straddle Price
$6.72
P/C Vol Ratio
0.92
Open
$54.91
Day Range
$53.15 – $54.92
Volume
20,888
Prev Close
$54.19
About

ProShares Ultra NASDAQ Biotechnology (BIB) ETF

No description available.

Exchange
XNAS
Inception
2010-04-06
Has Options
Yes
Fund profile
holdings as of Nov 18, 2026issuer datathrough Aug 2026flows, SEC filings
Leveraged & Inverse Leveraged Equity#47 of 160 by assets ProShares NASDAQ Biotechnology US Index-tracking
Resets to 2x its benchmark's return each day. Over longer periods the result compounds and can differ sharply from 2x the benchmark, especially when it is volatile. Decay analysis
Expense ratio
0.95%
prospectus, filed Sep 25, 2026
Assets
$48M
shares × price, Nov 18, 2026
Trailing yield
0.21%
paid quarterly
Average daily volume
$937K
30 sessions
Holdings
253
top 10 are 155.7%
Listed
Apr 6, 2010
Nasdaq
Closure risk, 12 months
1.0%
low: volatility · model
FrenzyCap ETF score
43
how it is built
Cost62
Liquidity32
Scale25
Diversificationn/a

Moves with. US large-cap stocks (17% of its variance, beta 1.19); Small caps over large (11% of its variance, beta 1.14); Long Treasuries (6% of its variance, beta 0.84). These factors explain 39% of its daily moves over the last year.

Stated objective. ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index (the Index). (from the fund's prospectus)

All 253 holdingsFlow historySimilar fundsOverlap toolAll Leveraged Equity ETFs

Fund flows
through Aug 2026SEC filings
Aug 2026
+$7.0M
latest reported month
Latest 3 months
+$1.5M
+1.5% of assets
Latest 12 months
−$7.3M
−7.2% of assets
Sep 2025: $0Oct 2025: −$36KOctNov 2025: +$6.1MDec 2025: −$6KDecJan 2026: −$59KFeb 2026: −$889KFebMar 2026: −$4.0MApr 2026: −$5.1M−$5.1MAprMay 2026: −$4.8MJun 2026: −$3.6MJunJul 2026: −$1.9MAug 2026: +$7.0M+$7.0MAug
View as a table
Net flows of BIB by month, Sep 2025 to Aug 2026
MonthNet flow
Aug 2026+$7.0M
Jul 2026−$1.9M
Jun 2026−$3.6M
May 2026−$4.8M
Apr 2026−$5.1M
Mar 2026−$4.0M
Feb 2026−$889K
Jan 2026−$59K
Dec 2025−$6K
Nov 2025+$6.1M
Oct 2025−$36K
Sep 2025$0

Net creations and redemptions from the fund's SEC filings, which become public about 60 days after each quarter. Every month since 84 months ago

Similar funds
FundOverlapFeeAssets1Y
IBBQInvesco Nasdaq Biotechnology ETF62%0.19%$123M+24.1%compare
IBBiShares Biotechnology ETF59%0.44%$10.9B+24.3%compare
BBHVanEck Biotech ETF38%0.35%$516M+29.8%compare
PBEInvesco Biotechnology & Genome ETF34%0.59%$422M+23.7%compare
XBIState Street SPDR S&P Biotech ETF33%0.35%$9.7B+26.3%compare

Ranked by how much of the two portfolios is the same securities.

Look-through: what the holdings say
weights as of Nov 18, 2026issuer data
Holdings vs fair value
+8.0%
33% under, 18% over · 100% covered
Price / earnings
—
51% loss-making · 94% covered
Price / book · sales
5.5 · 6.7
revenue growth +12.0%
Above 200-day average
80%
65% above 50-day · by weight
Short interest
7.8%
of float, weighted · 5.5 days to cover
Insider buying
5%
of weight had net insider buying, 90 days; 61% net selling
13F holders
+2.9%
change in shares held by institutions, latest quarter
Reporting earnings
0.0%
of weight in 7 days; 0.0% in 14
Largest contributors below fair value
Largest contributors above fair value
Holdings reporting in the next 14 days

Each figure is the fund's holdings weighted by position size, using our data on those stocks, and covers only the share of the stock holdings stated. Positive fair value means the holdings trade below our estimate.

What changed in the portfolio
Nov 13, 2026 → Nov 16, 2026
ActionHoldingWeight beforeWeight afterShares vs flows
ExitPCRXPACIRA BIOSCIENCES INC0.06%——

0 new, 0 exited, 0 increased and 0 decreased between the fund's two latest holdings reports; turnover 1.6%. Full holdings and history

Under the hood
fiscal year to May 31, 2026SEC census
Authorized participants
2 active
of 39 with agreements; top 3 did 100%
Created · redeemed
$11M · $23M
over the fiscal year
Redemptions in kind
99%
creations 96% in kind
Creation unit
10,000
shares
Securities lending
1.65%
of assets on loan on average; earned 4.0 bp
Return vs index
— pts
after fees; daily s.d. 19.46
Diversification status
Non-diversified
may concentrate in fewer issuers

From the fund's annual census filing with the SEC. In-kind redemptions are what let an ETF shed appreciated securities without realising gains.

ETF Profile
holdings as of 2026-11-17
Holdings
253
AUM
$226.6M
Provider
ProShares
Inception
2010-04-06
Exchange
XNAS
Data As Of
2026-11-17
Expense Ratio
0.95%
Dividend Yield
0.20%
Distribution
Quarterly
Recent distributions
Ex-Date Pay Date Amount Type
2026-09-23 2026-09-29 $0.0826 CD
2026-03-25 2026-03-31 $0.0071 CD
2025-12-24 2025-12-31 $0.1346 CD
2025-09-24 2025-09-30 $0.1805 CD
2025-06-25 2025-07-01 $0.1706 CD
2025-03-26 2025-04-01 $0.1309 CD
Asset Allocation
Top Holdings
top 50 of 253 holdings
Symbol Name Weight % Asset Class Country
— NASDAQ Biotechnology Index SWAP Bank of America NA 30.07% Derivative —
— NASDAQ Bio Index SWAP BNP Paribas 29.64% Derivative —
— NASDAQ Biotechnology Index SWAP Citibank NA 26.92% Derivative —
— NASDAQ Biotechnology Index SWAP Goldman Sachs International 19.14% Derivative —
— NASDAQ Biotechnology Index SWAP Societe Generale 18.23% Derivative —
IQMM PROSHARES GENIUS MNY MKT ETF 17.59% Cash/Money Market —
— Net Other Assets (Liabilities) 17.25% Cash/Money Market —
— NASDAQ Biotechnology Index SWAP UBS AG 10.22% Derivative —
GILD GILEAD SCIENCES INC 6.17% Equity (US) US
AMGN AMGEN INC 5.65% Equity (US) US
VRTX VERTEX PHARMACEUTICALS INC 5.20% Equity (US) US
REGN REGENERON PHARMACEUTICALS 4.20% Equity (US) US
MRNA MODERNA INC 3.58% Equity (US) US
BIIB BIOGEN INC 1.61% Equity (US) US
RVMD REVOLUTION MEDICINES INC 1.51% Equity (US) US
ILMN ILLUMINA INC 1.33% Equity (US) US
RPRX ROYALTY PHARMA PLC- CL A 1.33% Equity (US) —
ROIV ROIVANT SCIENCES LTD 1.21% Equity (US) US
INSM INSMED INC 1.15% Equity (US) US
ARGX ARGENX SE - ADR 1.12% Equity (US) —
UTHR UNITED THERAPEUTICS CORP 1.09% Equity (US) US
INCY INCYTE CORP 1.05% Equity (US) US
VTRS VIATRIS INC 1.02% Equity (US) US
ALNY ALNYLAM PHARMACEUTICALS INC 0.91% Equity (US) US
GH GUARDANT HEALTH INC 0.83% Equity (US) US
MEDP MEDPACE HOLDINGS INC 0.79% Equity (US) US
EXEL EXELIXIS INC 0.74% Equity (US) US
NBIX NEUROCRINE BIOSCIENCES INC 0.73% Equity (US) US
ASND ASCENDIS PHARMA A/S 0.72% Equity (Foreign) DK
JAZZ JAZZ PHARMACEUTICALS PLC 0.68% Equity (US) —
BBIO BRIDGEBIO PHARMA INC 0.67% Equity (US) US
ONC BEONE MEDICINES LTD-ADR 0.64% Equity (US) —
BMRN BIOMARIN PHARMACEUTICAL INC 0.49% Equity (US) US
TEM TEMPUS AI INC-CL A 0.48% Equity (US) US
HALO HALOZYME THERAPEUTICS INC 0.47% Equity (US) US
SNY SANOFI-ADR 0.44% Equity (Foreign) FR
KYMR KYMERA THERAPEUTICS INC 0.44% Equity (US) US
BNTX BIONTECH SE-ADR 0.43% Equity (Foreign) DE
MDGL MADRIGAL PHARMACEUTICALS INC 0.42% Equity (US) US
PCVX VAXCYTE INC 0.38% Equity (US) US
KRYS KRYSTAL BIOTECH INC 0.38% Equity (US) US
PRAX PRAXIS PRECISION MEDICINES I 0.37% Equity (US) US
SMMT SUMMIT THERAPEUTICS INC 0.37% Equity (US) US
SYRE SPYRE THERAPEUTICS INC 0.36% Equity (US) US
PTGX PROTAGONIST THERAPEUTICS INC 0.35% Equity (US) US
RYTM RHYTHM PHARMACEUTICALS INC 0.35% Equity (US) US
ALKS ALKERMES PLC 0.33% Equity (US) —
TWST TWIST BIOSCIENCE CORP 0.32% Equity (US) US
AMRX AMNEAL PHARMACEUTICALS INC 0.32% Equity (US) US
CYTK CYTOKINETICS INC 0.31% Equity (US) US
Geographic Breakdown
Non-Equity Breakdown
ProShares Ultra Nasdaq Biotechnology · NPORT-P period 2026-08-31 (filed 2026-10-28)
Net assets: $101M · 264 total positions · equity 54.37% · non-equity 39.45%
Non-equity holdings — 14 positions, 39.45% of NAV
Category Weight Value Positions
Repurchase agreement 22.21% $22.5M 5
Derivative (equity) 11.76% $11.9M 6
Other 4.94% $5.0M 2
Short-term investment 0.54% $542617 1
Chart

Markers: Click a marker type to show or hide it. Earnings turn amber when the stock moved more than options implied; hollow markers are still to come, or insider trades under a 10b5-1 plan. Intraday times are New York time; shaded bars are pre-market and after-hours.

Seasonality
Month'21'22'23'24'25'26Avg
Jan13.78%-24.35%8.37%-3.73%8.36%4.38%1.13%
Feb-7.31%-11.04%-12.93%-1.26%0.59%3.75%-4.70%
Mar-12.02%9.40%0.24%-4.28%-8.85%-6.66%-3.69%
Apr4.36%-22.60%1.29%-11.26%4.15%-1.16%-4.20%
May-4.34%-6.16%-7.70%6.68%-7.10%6.06%-2.09%
Jun17.97%2.70%-0.88%2.72%3.11%23.67%8.21%
Jul-3.05%3.37%2.89%12.92%8.84%-4.12%3.48%
Aug7.78%0.78%0.52%2.20%8.33%21.35%6.83%
Sep-11.42%-8.91%-9.76%-1.76%3.92%-2.61%-5.09%
Oct-0.45%14.18%-10.85%-4.66%14.17%9.11%3.58%
Nov-10.63%9.18%5.96%-3.47%20.14%-7.45%*2.29%
Dec1.17%-7.99%22.70%-15.16%-0.15%--0.11%
Total-8.96%-40.22%-5.18%-21.68%66.33%49.95%6.71%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $58.18
SMA 50: $56.56
SMA 200: $48.55
Current: $53.47
EMA 12: $56.88
EMA 26: $57.22
MACD: -0.3388 | Signal: -0.8161
BULLISH
ADX (14): 14.30
RANGE
+DI: 22.95
−DI: 32.88

Momentum Oscillators

RSI (14): 41.03
NEUTRAL
Stoch %K: 5.38
Stoch %D: 9.17
Williams %R: -96.68

Volume & Volatility

BB Upper: $63.49
BB Lower: $52.86
NEUTRAL
OBV: 901,151
Vol SMA 20: 16,458
Vol ROC: -70.99%
ATR: $2.28
True Range: $1.77
HV 20: 60.2%
HV 30: 61.4%
HV 60: 52.1%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-20T00:00:00 – 2026-11-18T00:00:00
AI Analysis

Click Frenzy-Pro™ for an AI analysis of this ticker.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

BIB Options Activity & IV Rank

BIB IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 56.8%
7-DTE IV: —
Expected Move: $6.72
7-DTE Move: $4.55
Days to Exp: 29 (2026-12-18)

Options Flow · All expiries

Call Volume: 25
Put Volume: 23
P/C Volume: 0.92
NEUTRAL
Call OI: 13
Put OI: 39
P/C OI: 3.0
Total OI: 52

ATM Options Pricing

ATM Call: $3.77
ATM Put: $2.95
Call %: 7.1%
Put %: 5.5%

Chain Summary

Chain Volume: 48
Chain OI: 52
Last Updated: 11/19/2026

BIB Implied Volatility

30-day IV
56.8%
Nov 19
IV rank
99High
Within its 90-session range

Loading implied volatility…

The 30-day IV is the at-the-money implied volatility of options 30 days out, the blue line. The band is its 20-session average, 2 standard deviations either side. Realized volatility is how much BIB actually moved over the last 20 sessions, from closing prices, on the same yearly scale. Without earnings takes each earnings report out of the 30-day IV, sized from what options paid for past reports, so it shows whether options are expensive or cheap apart from the report. Click a name above the chart to show or hide it.

Spread Scanner

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
HIGH γ vs HISTORY

Estimated net dealer gamma is at the 99th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
99%
vs own history
GEX tilt
+0.81
OI-weighted, today
Vanna tilt
+0.16
δ-sensitivity to IV
Charm tilt
-0.99
δ-decay vs time
Charm tilt -0.99: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 8 ATM contracts, 0k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Put vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol points

The same measure on the upside: how the OTM call is priced against the at-the-money strike.

  • Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
  • Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together

Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put —
— pts EXTREME
No data
30 DTE / 10d put —
— pts EXTREME
ATM 58.0% / Put —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)99.0HighNov 19

Embed BIB IV rank

BIB's 30-day IV rank (90 sessions) with its 52-week rank, at-the-money IV and a 90-session trend. Updates after each close. Paste the code into any web page or blog post. Email newsletters drop iframes, so link to the page there.

Theme
Preview
Straddle Price (30 DTE)$6.72Nov 19
Beta Analysis

Risk Metrics

Beta: 1.7198
Alpha: 24.98%
Correlation: 0.5052
R-Squared: 25.5%
Stock Volatility: 46.8%
Market Volatility: 13.8%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time

BIB Institutional Ownership (13F)

Filings for 2026-09-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

16 filers34,614 shares$3.89M value
# Filer Shares Value % of Total % of Float Period
1 Susquehanna International Group, LLP Custodian 7,802 $785.97K 20.22% — 2026-06-30
2 Jump Financial, LLC 6,736 $777.69K 20.01% — 2026-09-30
3 Capital Investment Advisors, LLC 5,696 $657.67K 16.92% — 2026-09-30
4 Kaizen Financial Strategies 5,315 $613.63K 15.79% — 2026-09-30
5 Palumbo Wealth Management LLC 4,000 $461.81K 11.88% — 2026-09-30
6 CHASE INVESTMENT COUNSEL CORP 2,400 $277.00K 7.13% — 2026-09-30
7 TOTH FINANCIAL ADVISORY CORP 1,022 $118.00K 3.04% — 2026-09-30
8 Franklin Resources, Inc. Custodian 696 $87.08K 2.24% — 2026-09-30
9 Ashton Thomas Private Wealth, LLC 373 $43.06K 1.11% — 2026-09-30
10 Harel Insurance Investments & Financial Services Ltd. 198 $23.00K 0.59% — 2026-09-30
11 Simplex Trading, LLC Custodian 137 $15.82K 0.41% — 2026-09-30
12 Truvestments Capital LLC 125 $12.59K 0.32% — 2026-06-30
13 UBS Group AG Custodian 48 $5.54K 0.14% — 2026-09-30
14 HARBOUR INVESTMENTS, INC. 45 $5.20K 0.13% — 2026-09-30
15 Tradewinds Capital Management, LLC 20 $2.31K 0.06% — 2026-09-30
16 Wells Fargo & Company Custodian 1 $65 <0.01% — 2026-06-30
2 filers$715.25K notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $413.03K 57.75% 2026-06-30
2 Citadel Advisors LLC Custodian $302.22K 42.25% 2026-06-30
# Filer Notional Value % of Total Period
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
10.12K
SI % of Float
1.15%
Days to Cover
1.10
Short Vol Ratio
26.2%
Free Float
—
Float %
—
Short interest 2026-10-30 • Short volume 2026-11-18
Constituent Performance

Click any bar to view the full quote for that stock.

Constituents
Symbol Name Weight % Price 1 Day 1 Week 1 Month